Welcome to our dedicated page for Telix Pharmaceuticals SEC filings (Ticker: TLPPF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Telix Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Telix Pharmaceuticals's regulatory disclosures and financial reporting.
Telix Pharmaceuticals Limited reports strong 2025 growth but lower profitability. Revenue rose to US$803.8 million, a 56% increase from 2024, driven by its Precision Medicine business and the RLS Radiopharmacies acquisition. Operating profit was US$29.8 million, yet higher R&D, manufacturing scale-up, and finance costs led to a net loss after tax of US$7.1 million, versus a US$33.7 million profit a year earlier.
Adjusted EBITDA declined to US$39.5 million as Telix increased R&D spending to US$171.2 million and expanded manufacturing infrastructure in the U.S., Europe, Japan, and Australia. Cash and equivalents fell to US$141.9 million from US$440.0 million, reflecting acquisition payments and capital investment, while the company continued advancing late-stage therapeutic trials and global product launches.
Telix Pharmaceuticals Limited submitted a European Marketing Authorization Application for its product candidate TLX101-Px, which is designed for brain cancer imaging. The company reported this regulatory milestone to U.S. investors by furnishing on Form 6-K the related announcement it filed with the Australian Securities Exchange.
Telix Pharmaceuticals Limited has announced a leadership change at the Board level. Ms. Tiffany Olson has resigned as Non-Executive Director and Board Chair, effective 3 February 2026.
Long-standing independent Non-Executive Director Dr. Mark Nelson has been appointed Interim Chair. The Board states it is in advanced stages of appointing new Non-Executive Directors and is committed to naming a new Independent Chair as soon as feasible. Dr. Nelson emphasized appreciation for Olson’s service and reiterated that Telix has a strong commercial business and pipeline, and that this governance change is not expected to affect delivery of near-term milestones or the company’s long-term growth strategy.
Telix Pharmaceuticals Limited filed a Form 6-K highlighting two key updates first released on the Australian Securities Exchange. The company reports that the Chinese National Medical Products Administration has accepted a New Drug Application for Illucix, marking an important regulatory step for this product in China. Telix also states that it achieved its FY 2025 guidance with US$804 million (A$1.2 billion) in revenue and is accelerating growth with the launch of Gozellix. Together, these disclosures point to strong recent commercial performance and progress in expanding the company’s product portfolio and geographic reach.
Telix Pharmaceuticals Limited submitted a foreign issuer report to the U.S. securities regulator to furnish investors with a copy of a presentation given at the JP Morgan Healthcare Conference 2026. The company states that it filed an announcement with the Australian Securities Exchange on January 12, 2026 titled “Telix JP Morgan Healthcare Conference 2026 Presentation,” and has attached this as an exhibit for U.S. investors. This filing is primarily administrative, making the same information available in the U.S. market that was released in Australia.
Telix Pharmaceuticals Limited submitted a Form 6-K to share with U.S. investors an announcement it filed with the Australian Securities Exchange. The attached announcement, titled “Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions,” outlines developments in Telix’s precision medicine portfolio. This report mainly serves to furnish that ASX announcement as Exhibit 99.1 for the U.S. market.
Telix Pharmaceuticals Limited submitted a Form 6-K to update U.S. investors on a clinical development milestone first disclosed in Australia. On December 8, 2025, the company filed an announcement with the Australian Securities Exchange titled “1st Patient Dosed in ProstACT Global Randomized Tx Expansion,” and this announcement is attached to the Form 6-K as Exhibit 99.1. The filing itself mainly serves as a cross-border notice and does not include additional financial results or transaction details beyond referencing the attached announcement.
Telix Pharmaceuticals Limited furnished a Form 6-K noting it filed an ASX announcement titled “Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded.”
The exhibit (99.1) highlights reported revenue of US$206 million and an upgrade to FY 2025 guidance, as described in the announcement title. Further operational or financial details are contained in the attached exhibit.
Telix Pharmaceuticals Limited reported that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through status for Gozellix. The company filed an announcement with the Australian Securities Exchange titled "CMS Grants Transitional Pass-Through Status for Gozellix," and the related press release is attached as Exhibit 99.1 to the report. No financial metrics, guidance, or additional transaction details are included in the filing.